Sucralfate pp 133-140 | Cite as

Sucralfate and Helicobacter pylori

  • J. A. Louw
  • G. O. Young
  • T. A. Winter
  • I. N. Marks


The reason for the lower relapse rates following duodenal ulcer healing with the mucosal protective agents, as opposed to the H2 receptor antagonists (H2RAs), is unclear. The quality of ulcer healing has been shown to be better following healing with colloidal bismuth and sucralfate1,2 and the tendency to “acid rebound” following withdrawal of the H2RAs may have some relevance. A further consideration relates to the antimicrobial effect of the mucosal protective agents on H. pylori, at least as far as colloidal bismuth preparations are concerned.


Duodenal Ulcer Triple Therapy Urea Breath Test Pylorus Colonization Duodenal Ulcer Healing 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Moshal MG, Gregory MA, Pillay C, et al: Does the duodenal cell ever return to normal? A comparison between treatment with cimetidine and DeNol. Scand J Gastroenterol 54(suppl):48–51, 1979. The ultrastructure of the duodenal cell was found to be normal in most cases following 6 weeks of De Nol therapy, whereas it remained abnormal after cimetidine therapy of similar duration.Google Scholar
  2. 2.
    Tovey FI, Husband EM, Yiu YC, et al: Comparison of relapse rates and mucosal abnormalities after healing of duodenal ulceration and after one year’s maintenance with cimetidine or sucralfate: A light and electron microscopy study. Gut 30:586–593, 1989. Duodenal mucosal biopsies abnormal after healing; on maintenance therapy, sucralfate-treated duodenal mucosa approached control mucosa characteristics, whereas cimetidine-treated mucosa did not (sucralfate group = 24, cimetidine group = 22).PubMedCrossRefGoogle Scholar
  3. 3.
    Evans DG, Evans DJ, Houlds JJ, et al: N-Acetylneuraminyl-lactose-binding fibrillar hemagglutinin of Campylobacter pylori: A putative colonization factor antigen. Infect Immun 56:2896–2906, 1988. Clinical isolates of H. pylori possess a cell-bound hemagglutinin with fibrillar morphology, which preferentially binds to isomers of N-acetylneuraminyl-lactose.PubMedGoogle Scholar
  4. 4.
    Saitoh T, Sugano K, Natomi H, et al: Glyco-sphingolipid receptors in human gastric mucosa for Helicobacter pylori. Eur J Gastroenterol Hepatol 4(suppl 1):S49–S53, 1992. Demonstrates, by thin-layer chromatography immunostaining, that H. pylori binds specifically to sulfatide and GM3 ganglioside in human gastric mucosa.Google Scholar
  5. 5.
    Lingwood CA, Lau H, Pellizzari A, et al: Gastric glycolipid as a receptor for Campylobacter pylori. Lancet 2:238–241, 1989. Reports differential gastric distribution of glycerolipid substance, which is specifically recognized by H. pylori.PubMedCrossRefGoogle Scholar
  6. 6.
    Slomiany BL, Piotrowski J, Samanta A, et al: Campylobacter pylori colonization factor shows specificity for lactosylceramide sulfate and GM3 ganglioside. Biochem Int 19(4):929–936, 1989. Helicobacter pylori hemagglutinin activity inhibited by lactosylceramide GM3-ganglioside, as well as by sucralfate.PubMedGoogle Scholar
  7. 7.
    Nakajima M, Sunairi M, Tanaka N, et al: Effects of sucralfate, an anti-ulcer agent, on Helicobacter pylori. Gastroenterology 102(4):A131, 1992. Sucralfate components inhibit the adhesion of H. pylori to mucosal surfaces, in vitro.Google Scholar
  8. 8.
    Berstad A, Alexander B, Weberg R, et al: Antacids reduce Campylobacter pylori colonization without healing the gastritis in patients with non-ulcer dyspepsia and erosive prepyloric changes. Gastroenterology 95:619–624, 1988. Aluminum-magnesium-containing antacid decreases density of H. pylori colonization. No improvement in inflammatory reaction noted.PubMedGoogle Scholar
  9. 9.
    Berstad K, Weberg R, Berstad A: Suppression of gastric urease activity by antacids. Scand J Gastroenterol 25:496–500, 1990. Employs [14C]urea breath test to demonstrate a short-lived reduction in 14C recovery following treatment with aluminum-magnesium antacid.PubMedCrossRefGoogle Scholar
  10. 10.
    Tytgat GNJ, Noach LA, Rauws EAJ: Helicobacter pylori. Eur J Gastroenterol 4(suppl 1):S7–S15, 1992. Review of the general state of knowledge regarding the pathogenesis of H. pylori infection, potential treatment strategies, and implications of eradication.Google Scholar
  11. 11.
    Tsuji S, Kawano S, Tsuzu M, et al: Sucralfate is an ammonia scavenger and protects gastric mucosa from ammonia-induced injury. Gastroenterology 102(4):A706, 1992. Cotreatment of rats with sucralfate or ranitidine prevents ammonia-induced gastric mucosal injury; sucralfate claimed to be ammonia scavenger in vitro.Google Scholar
  12. 12.
    Piotrowski J, Yamaki K, Slomiany A, et al: Inhibition of gastric mucosal laminin receptor by Helicobacter pylori lipopolysaccharide: Effect of sucralfate. Am J Gastroenterol 86(2):1756–1760, 1991. In vitro evidence that lipopolysaccharide from H. pylori interferes with laminin/integrin binding; this inhibition of binding prevented by sucralfate.PubMedGoogle Scholar
  13. 13.
    Slomiany BL, Piotrowski J, Slomiany A: Effect of sucralfate on the degradation of human gastric mucus by Helicobacter pylori protease and lipases. Am J Gastroenterol 87(5):595–599, 1992. In vitro evidence that sucralfate is capable of counteracting the mucolytic activity of H. pylori-derived enzymes to human gastric mucus proteins and lipids.PubMedGoogle Scholar
  14. 14.
    deKorwin JD, Vicari FI, Chambre V, et al: Follow-up of Campylobacter pylori gastric infection after treatment of gastroduodenal ulcers with sucralfate or H2-antagonists, in Mégraud F, Lamouliatte H (eds): Gastroduodenal Pathology and Campylobacter pylori. Amsterdam, Elsevier Science Publishers, 1989, pp 619–623. Retrospective study on 28 H. pylori-positive gastric and duodenal ulcer patients, treated with H2-receptor antagonists or sucralfate for a period of 6 weeks. Clearance noted in 7 of 16 sucralfate-treated patients and 1 cimetidine-treated patient. H. pylori detection by scanning electron microscopy.Google Scholar
  15. 15.
    Kjoller M, Nielsen L, Kristensen E, et al: DeNol versus Antepsin in the treatment of gastric ulcer. World Congresses of Gastroenterology, Sydney, Australia, August 26–31, 1990, PD307. Gastric ulcer patients (n = 97) treated with either De Nol or Antepsin for a maximum of 60 days. Clearance rate of 56% in the De Nol group and 47% in the sucralfate-treated group. Method of H. pylori detection not specified.Google Scholar
  16. 16.
    Hui WM, Lam SK, Ho J, et al: Effect of sucralfate and cimetidine on duodenal ulcer associated antral gastritis and Campylobacter pylori. Am J Med 86(suppl 6A):60–65, 1989. Antral colonization density of H. pylori decreased significantly after sucralfate 1 g qid for 4 weeks, but not after cimetidine 200 mg tid and 400 mg nocte.PubMedCrossRefGoogle Scholar
  17. 17.
    Winter TA, Louw JA, Marks IN, et al: The effect of sucralfate on Helicobacter pylori status and gastritis in duodenal ulcer patients. S Afr Med J 83:784, 1993. Decreased histologically assessed density of H. pylori colonization in the antrum following 6 weeks of sucralfate therapy.Google Scholar
  18. 18.
    Banerjee S, El Omar E, Mowat A, et al: Sucralfate suppresses H. pylori infection and reduces gastric acid secretion by 50% in DU patients. Gut (suppl 2):S35, 1994. Decreased histologically assessed antral H. pylori colonization density and urea breath test levels in 11 sucralfate-treated subjects.Google Scholar
  19. 19.
    Dorval ED, Barbieux JP, De Muret A, et al: Long term results of a triple therapy using sucralfate on Helicobacter pylori eradication and healing of duodenal ulcers (DU). Gastroenterology 100:A55, 1991. Preliminary report evaluating nine patients.Google Scholar
  20. 20.
    Louw JA, Zak J, Lucke W, et al: Triple therapy with sucralfate is as effective as triple therapy containing bismuth in eradicating Helicobacter pylori and reducing duodenal ulcer relapse rates. Scand J Gastroenterol 27(suppl 191):28–31, 1992. Comparable eradication rates found in 20 sucralfate-and 20 bismuth-treated patients.CrossRefGoogle Scholar
  21. 21.
    Stupnicki TH, Taufer M, Denk H, et al: Triple therapy of duodenal ulcer with sucralfate and amoxycillin plus metronidazole. Abstract, 7th International Sucralfate Symposium, Santa Barbara, 1994. Forty-four of fifty-six patients treated with sucralfate based triple therapy successfully eradicated.Google Scholar
  22. 22.
    Hui WC, Lam SK, Ching CK, et al: Omeprazole or sucralfate combined with clarithromycin and metronidazole in Helicobacter pylori eradication and ulcer healing. J Gastroent Hepatol 9:A11, 1994. Eradication achieved in 86% of patients treated with a sucralfate-based triple therapy compared with 87% in an omeprazole-based group.Google Scholar
  23. 23.
    Sung JY, Ling TKW, Suen R, Chung SCS: Can sucralfate replace bismuth in triple therapy for the treatment of Helicobacter pylori associated duodenal ulcers? Abstract, 7th International Sucralfate Symposium, Santa Barbara, 1994. 84% eradication with sucralfate-containing triple therapy, followed by sucralfate-healing therapy, versus 100% eradication in patients treated with bismulh-containing triple therapy and omeprazole cotreatment for healing.Google Scholar
  24. 24.
    Bayerdörrfer E, Mannes GA, Sommer A, et al: High dose omeprazole treatment combined with amoxicillin eradicates Helicobacter pylori. Eur J Gastroenterol Hepatol 4(9):697–702, 1992. Eighty-two percent eradication reported in 27 patients treated with high-dose omeprazole (80 mg/day × 10 days, 20 mg/day for rest of 6-week period) in combination with amoxicillin, 1 g bid for the first 10 days. No side effects reported.Google Scholar

Copyright information

© Plenum Press 1995

Authors and Affiliations

  • J. A. Louw
    • 1
  • G. O. Young
    • 1
  • T. A. Winter
    • 1
  • I. N. Marks
    • 1
  1. 1.Gastrointestinal Clinic and Department of MedicineUniversity of Cape Town and Groote Schuur Hospital, ObservatorySouth Africa

Personalised recommendations